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Background: The main objective of this study is to gain further insights on how
chronic myeloid leukemia (CML) patients involved in an interventional clinical trial with the
purpose of reaching treatment free remission (TFR) phase, perceived and experienced
TFR failure. TFR failure was defined for the individual patient as either not being eligible
for drug discontinuation or as having relapse in the TFR phase with reintroduction of
nilotinib treatment.
Methods: Using a qualitative approach, out of 25 patients with CML who experienced
TFR failure 14 were interviewed. Patients’ views and experiences were explored using
in-depth interviews, analyzed using the Interpretative Phenomenological Analysis (IPA).
Results: The analysis of the interviews revealed that the experience of the diagnosis
seems to have been lived as a traumatic break that has created a dichotomy, like an
ambivalence in the ways in which CML patients perceived and experienced the whole
disease journey, with contradictory feelings of both positive and negative emotions (e.g.,
a diagnosis of cancer, that is something distressing and of being afraid of, but also
with a treatment and a life expectancies of which being grateful). This ambivalence
of feelings was found to give meaning to the way in which patients cognitively and
Frontiers in Psychology | www.frontiersin.org 1 February 2019 | Volume 10 | Article 329
fpsyg-10-00329 February 19, 2019 Time: 12:3 # 2
Borghi et al. CML Patients Experience TFR Failure
emotionally experienced the different steps of their disease history. Thus, four main
issues, corresponding to different steps of the patients’ journey, were identified: (1)
the moment of the diagnosis, (2) the experience of the illness journey: disease and
treatment, (3) the moment of “TFR failure,” and (4) the impact of disease, treatment and
relapse on the patient’s life.
Conclusion: This qualitative analysis helps in understanding patients’ perspective, both
in terms of getting access to the inner subjective experience of having CML and its strict
relationship with the involvement in a trial or its cessation. Clinicians should consider that
the way in which CML patients feel engaged in a clinical trial, create expectancies about
TFR or experience the TFR failure is linked to the process of coping with the diagnosis,
which is characterized by ambivalence.
Keywords: chronic myeloid leukemia, nilotinib, ENESTPath, TFR, inner emotional experience, psycho-emotional
outcomes
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloid neoplasia
characterized by the mutual translocation between chromosome
9 and 22 (Philadelphia chromosome) and by the BCR-ABL1
rearrangement, with a consequent synthesis of an uncontrolled
tyrosine-kinase that induces increased proliferation, reduces
apoptosis, and causes the entry of myeloid immature cells into
the bloodstream (Rowley, 1973).
In the last decades, thanks to the introduction of first-
generation tyrosine kinase inhibitors (TKIs) (imatinib), the
molecular-targeted therapy in CML became a reality, with the
consequent improvement of the outcome for more than 90%
of cases. Notwithstanding imatinib already greatly improved
overall survival and allowed patients to achieve high clinical
response rates (Hanfstein et al., 2012), the introduction of
second-generation TKIs (nilotinib and dasatinib) as first-line
therapy allowed a higher percentage of patients to achieve deeper
and faster molecular responses (MR). The excellent treatment
option provided by TKIs are offering a survival comparable to
that of the general population (Bower et al., 2016).
The newest guidelines of the National Comprehensive Cancer
Network [NCCN] (2018) and of the European Society For
Medical Oncology (ESMO) (Hochhaus et al., 2017) have recently
proposed criteria for potential treatment discontinuation. In
fact, in the latest years many studies clearly showed that about
half of patients who achieved a sustained and deep molecular
response (DMR) can discontinue treatment without losing their
DMR, thus making the treatment-free remission (TFR) a reality.
As recently published data suggest that the duration of DMR
(Saussele et al., 2017) is important for maintaining TFR, the data
derived from the ENESTPath trial will provide further insights.
The primary objective of this trial is to elucidate the optimal
duration of consolidation treatment before TFR attempt. Several
variables have been identified as fundamental presupposition
for TFR (length of therapy, depth of MR, type of TKI, line of
treatment). Available data is mostly derived from interventional
clinical trials with only Nilotinib having clear guidance for the
TFR eligibility and the discontinuation procedure in the officially,
health authority approved Summary of Products Characteristics,
thereby leaving the process of decision making about interruption
to each physician-patient dyad.
It is not difficult to imagine the emotional distress that this
decision could induce, where patients could live this proposal
as an unexpected and positive option, while others might see
this moment as uncertain or risky. While patient’s view in the
management of treatment has been well recognized even by the
authorities that included patient reported outcomes (PRO) in
the process of the new drug submission packages and regulatory
approvals (Amir et al., 2012), there is still a lack of knowledge
about the factors affecting emotional well-being of participants
to clinical trials (Hopwood and Thatcher, 1990; Aaronson, 1992;
Kaasa, 1992; Cox, 2003; Wineman et al., 2003). Most of the
published studies use quantitative instruments to mainly assess
quality of life (QoL), with only few stressing the importance
of a qualitative methodology to enhance the comprehension
of patients’ inner experience. A study published in 2003 (Cox,
2003) analyzed the emotional experiences of patients enrolled
in phase I/II oncological trials. While the data obtained from
the questionnaires revealed no changes over time, in-depth
interviews adequately sketched some otherwise hidden aspects
of the psychological, emotional, and social impact deriving
from participation in a clinical trial from the perspective of
the patient (Cox, 2003).
Focusing on CML, the majority of the already published
studies assessed QoL using quantitative methods, such as the
EORTC QLQ-CML24 (Efficace et al., 2012, 2014), FACT-
LEU (Trask et al., 2013), or SF-36 (Ware and Sherbourne,
1992) questionnaire, producing some interesting results. In
particular, these studies pointed out a lack of knowledge about
TFR, as its emotional perception is yet to be adequately
evaluated: in a series of 87 patients, 81% of them indicated
that they would be willing to attempt TFR, especially those
who experienced previous toxicities. On the other hand,
the reluctance to discontinue treatment was often associated
with a need for additional information and perhaps with a
not fully confident relationship with the respective referent
physician (Villemagne Sanchez et al., 2018).
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In this panorama, we conducted a multilevel study employing
a quantitative and qualitative approach for exploring CML
patients’ psycho-emotional outcomes, QoL and inner experiences
involved in different moments of disease history. In particular,
the aim of this contribution is to present results from qualitative
interviews about the subjective emotional experience of those
patients who experience the TFR failure.
MATERIALS AND METHODS
Study Design
The present contribution is part of an Italian sub-study
examining patients’ psychological and emotional characteristics,
involved in ENESTPath trial, a phase-3 European multicenter
clinical trial involving 620 patients from 22 different countries.
Enrolled patients received 12 months of nilotinib 300 mg BID as
induction phase followed by further 12 months of consolidation.
Patients achieving a sustained DMR (≥MR4 in 4 of 5 PCR
assessments, including the last assessment, in the last 12 months)
at the end of the first 24 months of treatment were either
randomized to a further consolidation period of 12 months
(Arm 2, 36 months of total treatment time) or discontinued
immediately for TFR (24 months of total treatment). The primary
endpoint of the ENESTPath is the assessment of the potential
impact of a longer duration of consolidation (12 months vs.
24 months) on molecular relapse rate in the first 12 months of
TFR (>MMR). All patients not in a stable MR4 and therefore
not eligible for randomization according to the above mentioned
criteria had to discontinue the trial.
The Italian sub-study involved 31 patients and assessed
patients’ emotional experience during and after stopping
nilotinib, and after trail discontinuation. To obtain a
comprehensive evaluation of patients’ psycho-emotional
outcomes and adopting a multilevel perspective, both
quantitative (questionnaires) and qualitative (expressive
writing and interviews) methods have been used.
This paper presents qualitative data gained from the
interviews on patients who “failed” the trial, i.e., patients who had
to start retreatment with Nilotinib because they relapsed in the
TFR phase or patients who had to discontinue the trial because
they were not eligible for randomization by month 24 after the
induction and consolidation phase.
Participants
Participants are all patients enrolled in the Italian sub-study
who accepted to be interviewed because they experience the
psychological phenomenon of “TFR failure” as they were
ineligible for the randomization (unstable MR4 during the
consolidation, early discontinuation of the main study: End of
Phase – EOP) or they relapsed during TFR (loss of MMR,
or the confirmed loss of MR4). Patient recruitment relied on
convenience sample, as the group of interest was limited, as
only Italian patients were involved. Participants were enrolled
according to the maximum variability criterion, unless data
saturation of the following variables: patients’ gender, patients’
age, years since CML-diagnosis.
The study was carried out in accordance with the GCP rules.
As the Italian substudy is multicentric and involved many Centers
(hospitals) all around Italy (Bari, Bologna, Cona, Livorno, Milano
2 Hospitals, Mirano, Orbassano, Pagani, Parma, Pavia, Perugia,
Pescara, Pisa, Reggio Emilia, Roma 2 Hospitals, Taranto, Verona,
Vicenza), the research protocol was approved by the Health
Authorities, by the Ethics Commitee of the coordinator site (AO
Università di Bologna Policlinico S. Orsola – Malpighi, Bologna,
Italy) and by all the Ethics Commitee of all the involved Hospitals.
All subjects gave written informed consent in accordance with the
Declaration of Helsinki.
Data Collection
Adopting a qualitative–interpretative methodology, in-
depth unstructured interviews were conducted within one
month from the trial discontinuation to explore patients’
emotional experience of the phenomena “being ineligible for
randomization” or “failing TFR.” In-depth interviews have been
widely used in the medical literature (Greenhalgh and Hurwitz,
1999), in particular when the aim is to reconstruct the meanings
patients given to their experiences. Narration approach allows
the speaker to reconstruct and reinterpret past, present and
future events, making them understandable and communicable.
Interviews were guided using open-ended questions (e.g., “Tell
us about your illness experience, including the last trial period,
starting from the point that is more important for you”) and
followed patients’ narrative flow; the interviewer only facilitated
the narration. Patients were asked to describe the course of their
disease and their involvement in the clinical trial, including the
final moments of trial discontinuation. Interviews were audio
recorded and fully transcribed verbatim.
Data Analysis
Verbatim reports were analyzed according to the principles of
Interpretative Phenomenological Analysis (IPA) (Smith, 1996;
Eatough and Smith, 2008; Smith et al., 2009), an inductive
method of analysis that through an in-depth interpretation of
individual narratives allows grasping the essence of how people
attribute sense to their experiences (Conroy, 2003; Richards and
Morse, 2007). IPA is based on the hermeneutic-phenomenology
approach, in which a double hermeneutic focus is applied:
the analyst interprets the participants’ interpretation of their
lived experience. IPA is a widely used approach to qualitative
research in health psychology, as it is particularly suited to
discovering subjective processes through which patients make
sense of their symptoms or diseases (see, for example, Griffiths
et al., 2011; Hilgart et al., 2013; Vegni et al., 2013). For this
reason, a level of homogeneity of experience (in this specific
case, CML patients experiencing the discontinuation or return to
treatment) is important in order to ensure access to a comparable
experience across the group as a whole. Through the process of
IPA, it is possible to uncover implicit beliefs and emotions that
are carried in the stories by the deep analysis of their verbal
statements, although writers are not necessarily completely aware
of these psychological states from a cognitive viewpoint (Smith
and Osborn, 2007). The analysis proceeds as a spiral from details
to the whole, from one theme to the complexities of theme, from
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narratives to concepts, and again to narratives. Indeed, IPA is an
iterative inductive process that starts from the detailed reading
of the texts aimed at gaining a holistic understanding of all the
collected narratives (Eatough and Smith, 2008).
In the present study, complete verbatim reports of the
interviews were independently analyzed by two researchers
(LB and EV), one of whom conducted the interviews. In
the early stage of the analysis, the researchers took notes
of their understanding of the text and of their preliminary
insights about the meanings that participants attribute to
their experience. A detailed case-by-case analysis of individual
transcripts was conducted with the aim of identifying perceptions
and emotions of patient’s journey through CML and the
tria. Adeeper analysis was then conducted in order to
further understand patient’s experience. Core themes were
generated in two ways: (1) by clustering similar themes of
the various accounts into more exhaustive categories, and (2)
by formulating an interpretative hypothesis based on issues
whose sense could not be understood separated but were
instead interpreted globally as a whole. Preliminary results
were discussed in depth adopting a triangular approach (a
third researcher -SG- was involved), to reach an agreement
on the themes. The analysis process was conducted during
the final stage of data collection in order to verify the
hypotheses that emerged from the interpretation process with
patients. Finally, excerpts of the accounts were selected to
exemplify the results.
RESULTS
The psychological Italian sub-study of ENESTPath enrolled 31
patients, of whom 25 patients experienced TFR failure; out of
these 14 were interviewed as far as the phenomenon of TFR
failure, including 8 ineligible for randomization due to unstable
molecular response, and 6 patients who relapsed during TFR and
had to be retreated. Patients were 11 males and 3 females, with
a median age of 57.5 (range 36–82), and a relatively long history
of disease (median = 10 years, range 3–15). Patients were mainly
married (85.7%), with a medium-high educational level (58.3%
high school, 25% graduates). The mean length of the interviews
was 39′53′′, ranging from 28′07′′ to 53′54′′.
The analysis of the interviews revealed an underlying theme
that runs across the whole disease history, from the moment of
the diagnosis to the experience of “TFR failure” due to unstable
MR4: a dichotomy, like a split that seems to originate from a sort
of traumatic break experienced by patients when they faced the
CML diagnosis. This ambivalence of contradictory feelings with
both positive and negative emotions (e.g., a diagnosis of cancer,
that is something distressing and of being afraid of, but also
with a treatment and a life expectancies of which being grateful)
characterized the way in which CML patients cognitively and
emotionally perceived and experienced the different steps of their
disease journey.
Thus, four main issues, corresponding to different steps of
the patients’ journey, were identified: (1) the moment of the
diagnosis, (2) the experience of the illness journey: disease and
treatment, (3) the moment of “TFR failure,” and (4) the impact of
disease, treatment and relapse on the patient’s life.
Experience of the Diagnosis
The first interesting observation is that all interviewed subjects,
when asked to talk about the early “TFR failure,” started
their narration from the experience of the diagnosis. Indeed,
the majority of patients remembered the diagnosis itself in a
dichotomous way: as a traumatic experience (in which the weight
was greater when the patient’s perspective was far from that
hypothesis), but at the same time as something wrong that was
rapidly overcome, as “all goes well.”
“The doctor called me and told me it was leukemia... that moment
was a blow, because I was really far from that hypothesis” [5].
“Fifteen years ago, when they told me I had this disease, I took
it kind of hard at first, because I started to think about why this
disease came huh... and I was worried I would no longer have that
tranquility I had before” [6].
Interestingly, the words related to the diagnosis were not
emotionally charged, but rather they appeared in a metaphoric
and evocative way.
“I took two days to do all the investigations... it was just the day
when the Twin Towers tragedy happened, I just saw it, I was
hospitalized... in fact a parallelism.” [4]
Moreover, it was a seemingly common aspect that the moment
of the diagnosis was not remembered in its details; nobody
fixed the narration on the way or the sentences that the
physician used for communicating the CML presence, as if that
moment still represented a trauma from which patients tried
to defend themselves from; however, patients still remembered
doctors’ reassurances.
“The doctor told me: ‘yes you have leukemia... but... not all patients
have the same leukemia, you have this type (CML), the others have
the worst, you the best... you have to fight for your life . . .”’ [9].
“In the second visit after the exams the doctor wanted to explain to
me... he reassured me, he said ‘no. . . ’, he explained me that there’s
like a crazed chromosome called Philadelphia that creates these...
overhangs.. and he told me... ‘we have to keep it under control’...
he just diagnosed me with chronic myeloid leukemia and told me it
was not at acute levels, that it was not, well... serious, it was only to
be taken care of, to be kept under observation and to be followed by
a therapy” [11].
“The first moment I huh...I did not care so much, maybe because
huh...the physician said to me ‘don’t worry, it’s not (serious), but
you must do the blood tests’ ... later...when they told me the effective
diagnosis hum... huh... I went home and I started crying” [11].
Finally, regarding the strategies used in coping with the
diagnosis, patients reported to face the disease as something
unexplainable and so difficult to control, lived in a passive way
but precisely for these reasons they faced the diagnosis denying
and minimizing its load.
“It was a nonsense search, I realized it later, but it was the thing
that struck me most... looking for a cause that maybe there wasn’t...
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I thought the fault was mine, some negligence or something that had
brought me to the disease, the 40 years before... what was wrong?
Absurd to think but my thought was there...” [6]
“Initially this path was a little bit ‘... as in dealing with all the
diseases you always found difficulties. . .I made like a lineup to
understand how I had to go through my life, I told myself ‘I want
to face open-mouth or I want to drag myself throughout my life... I
told myself I am studying a path that would help me to leave this...
this difficulty that I have encountered” [7]
Experience of the Illness Journey:
Disease and Treatment
Patients perceived the disease as invisible, something that does
not affect their lives; at the same time, they had difficulties in
thinking or talking about death.
In particular, patients reported the difficulty in creating
a mental space to think about the disease during their life,
which is probably related to the unsolved process of coping
with the diagnosis.
“I want to continue, let’s say, I would like to continue hum... always
following that instinct that led me, when there are empty spaces
in which I’m not doing or thinking about something else, I have a
moment of reflection, to occupy thinking about new things and not
to what is happening to me, trying to continue my life normally...
until now I have succeeded” [6].
Some patients referred in an ambivalent way both to the
disease, as something present but not visible, and to the
treatment, as the thing that testifies the reality of the illness; at
the same time, therapy was something to be grateful for.
“[the disease] is like a daily and silent war because maybe from the
outside, all in all, it is not like those who do chemotherapy, it’s an
everyday war, twice a day you remember this thing, then, all in all,
I learned to live together with it, it becomes an automatic thing like
eating, drinking, so in short” [4].
“I am one in a million, a Highlander. . .” [14].
Thus, patients reported a good adaptation to the treatment,
something that began to be integrated in the patient’s life;
however, all the individuals referred to the treatment as essential
for life and survival.
“Doctors proposed to me to move on to this new drug and. . .I can
say that I lived in a positive way even if at home I was afraid to
take this new substance...let’s say yes, it was something dramatic
rather than tragic; however, I learned to live with it, just because
I saw that there was this drug I did not live it [bad]...it started to
be part of me” [4].
“The drug was a perfect cure . . . it was a life saver” [1]
“We were in the Amazon rainforest and I told a friend ‘this drug
is a lifesaver for me, that’s what I need to take!’ I have it with
me but I might lose this backpack so... please carry a dose for
me...just in case.” [2]
Experience of TFR Failure
Patients’ perception of the TFR failure, its meaning and its
impact can be understood when their individual experience
and disease history are considered. In particular, the
experience of failure proved to be linked to the imagined
or lived experience of stopping treatment. Patients’
experience of failure always reflects a slightly negative
emotional experience.
“I did not see it (the trial discontinuation) in such a negative, such
a dramatic way that I would say ‘from now on how will I cope with
life? How will I do it?’ I accepted it pretty well, I think I accepted it
well. . .because undoubtedly that day that doctors told me about the
disease I thought... I said: ‘Why I got sick?”’ [9]
“This course of treatment presented some negativity, some aspects
that could create me psychological difficulties... these things here
(sexual difficulties)... it was not a path just so negative or so
positive... a normal path, let’s say” [6].
Patients referred to the trial discontinuation as “a little bit
of. . .not dejection. . .but a bitter pill” and as “stumbling” during
the care pathway.
“I have lived the path a bit like a bicycle climb... you come halfway
up and they tell you that the road is closed... it left me a little
bit like this...” [12].
“Undoubtedly you hope... how can I say . . . you let yourself believe
that you manage to suspend the drugs and return to life...actually
I have a normal life, I have only to take these pills but my life is in
some way normal. . .we have tried to remove it completely, it did
not happen and I went ahead in the same way” [6].
“If I have managed to be included in that group [of patients eligible
for TFR] I would have lived it a bit like a prize after so many years
of treatment, then, all in all, compared to other situations I tend to
say ‘I have to thank for it’...that’s ok after all” [4].
“When I was small, I had a puppet of the type that, when you
beat him, always gets back on its feet... I am like this puppet
who always puts himself in position... I do not know if it’s
thoughtlessness” [2].
The ambivalent view of the clinical trial and of patient’s
early discontinuation was also related to the comforting
feeling of being engaged and more closely cared for during
the trial, so that the discontinuation has been seen as
“an abandonment.”
“This [EOP] has a little ‘knocked out because hum... because I felt
good, I felt followed and the check-ups were often... and now I
see myself as a bit’ set aside. I always continue with the pills and
my therapy, but I am no longer part of this protocol, I am a bit
‘thrown down” [11].
The perception of unpleasantness gains meaning when linked
to the idea of stopping treatment, which is seen as something
useful but at the same time demanding: the therapy often appears
to be the only sign that still remind of the presence of the
disease, but it also represents a sort of “comfort zone” for
patients, something they are used to, and that represented a
sort of lifesaver.
“I suspended the treatment for a week... and now I’ll have to restart
with it; however, I... I’m in doctors’ hands because... they are the
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ones who give me life... if I suspend [the treatment] I know that the
disease will reappear within a month” [9].
The Impact of Relapse on the
Patient’s Life
CML was perceived as something invisible but present,
like a ghost that permits us to conduct normal lives but
at the same time undermines future plans, changing the
perspective in which patients live their lives; patients reported
to live for the day, without too many expectancies or long-
term plans.
“I don’t want to have high expectations or hopes, I follow the course
of events. . .I say to myself ‘let’s see if it is something that can lead
me towards something good. You will discover it by living” [10].
“Honestly I am living my life day by day... I do not expect to do great
things later because I do not know if... if I will get there... I do not
have... thoughts about the future... tomorrow is another day... as the
disease has a sudden outbreak” [9]
“They reassured me saying that there are other drugs. . .let’s say,
I don’t live the day without worries about the future, because
obviously I think about the future” [4].
“The road has changed... for e.g., Italy is now a country where work
is not easily found. I am going to look for work somewhere else, gain
experience abroad. However, there is always this unknown about
going abroad as I always have this factor (disease) to consider” [8].
In particular, the disease seems to have a sort of deadly effect
on the procreative plans, and reproductive successes appeared to
be “miracles.” Moreover, with regard to their children, patients
reported to be worried about not being able to fully perform their
parental roles and functions.
“Since the beginning, they clearly told me that I probably would
not have children...I remember that in front of the doctor I started
crying, because maybe at 27 it was something that I was postponing
. . . I remember that I cried so much. . .then I started to accept the
idea. . .and that is not something I suffer from, but maybe if it did
not happen I would have had (a child) like everyone else” [4].
“After the illness, my wife and I decided not to have another child...
all in all it’s a small regret. But that’s ok” [3]
“They treated me... they gave me therapy . . . and I had a child...
that is, I managed to have a child...I thought that the child could
have problems and so on, but he was born healthy” [9].
“Sometimes, when I’m alone in my car, I also have these
weaknesses... like any human person, let’s say, I don’t rock the world
but I’m just starting to think, I’ve got my family... And I worry not
about myself but about my children” [6].
DISCUSSION
This sub-study represents one of the few available studies
that face up to the emotional aspects of living the CML
in the new era where TKIs offer a long survival with,
in the majority of cases, a good QoL. Despite new
drugs for CML offer high chances of optimal responses
(Hochhaus et al., 2016), our interviews suggest that
patients could experience emotional distress during the
illness journey.
We suggest that our qualitative approach allows to explore
the inner emotional experience in a way that integrates the
most common quantitative approach: through a bottom-up
method and a “majeutical”, way individuals could exteriorize
some introspective aspects adding additional information to the
a priori items of questionnaires.
In particular, it was interesting that at the beginning of the
narration, all patients remembered the moment of diagnosis,
even if the interviewer, thus exemplifying that this ghost still
survives even after several years of an effective treatment, did
not require it. On the other hand, in spite of the efficacy
results observed with nilotinib, in all cases the fear of long-term
planning remains, thus highlighting a further aspect previously
undetected by the literature based on quantitative methods
(i.e., questionnaires).
As for the diagnosis, it is true that our patients firstly
remembered the moment of the diagnosis as a shock, like
a traumatic break, which is difficult to express and that
probably is not yet metabolized, but our patients tried to
rapidly reorganize their lives around the idea that “CML
is curable, and thanks to the treatment they could have
the opportunity of conducting normal lives.” This result is
consistent with the findings of a recent study exploring, through
narrative diaries, both the impact of the disease on CML
patients’ everyday lives and the psychological impact of their
being presented with the chance to suspend their therapy
(Graffigna et al., 2017). The study highlighted how patients
described the communication of the diagnosis as a “bolt
from the blue,” something that was unexpected and disrupted
patients’ lives.
The drama of the diagnosis as lived by patients had
some common characteristics with the emotional experience of
receiving a piece of bad news. There is a wide literature on
bad news highlighting the fact that the doctor’s communication
of a bad news is worse (and the processing thereof more
difficult and traumatic) as the patients is farther from it
(Buckman, 1992). Indeed, CML patients usually did not
experience symptoms or problems before the diagnosis and
diagnosis often occurs by chance (e.g., regular blood tests or
blood donation). Buckman suggested that the physician should
left time and space to patients emotional reaction and processing
of the bad news during its communication (e.g., step-by-
step communication).
Moreover, CML patients reorganized their lives after the
diagnosis, and this process seemed to be driven by the
dramatic change of the CML panorama: the disease has
shifted from a mortal to a chronic condition, and nowadays
the perspective is that it could become curable. This rapid
progress seemed hard to integrate in patients’ mind, and
often did not settle in a congruent reorganization of the
patients’ perspective of disease. Some patients described their
CML experience as a “silent war”: this metaphor was often
retrievable in cancer patients’ narratives (Skott, 2002), and was
found to be particularly powerful in revealing CML patients’
Frontiers in Psychology | www.frontiersin.org 6 February 2019 | Volume 10 | Article 329
fpsyg-10-00329 February 19, 2019 Time: 12:3 # 7
Borghi et al. CML Patients Experience TFR Failure
illness experience (Graffigna et al., 2017). Indeed, it highlights
the ambivalence of the emotional and cognitive experience
of being a CML patient that originates from the moment
of the diagnosis, like a wound beyond healing. Our data
interpretation seems to be coherent with the whole illness
journey, particularly the ambivalent connection to the treatment
and its discontinuation.
Another innovative aspect of our study is that to our
knowledge it is the second study facing the TFR in CML
from the psychological point of view. The Australian
group (Villemagne Sanchez et al., 2018) recently reported
the answers from 84 patients on their feeling about the
TFR: half of them received imatinib, and the rest nilotinib
or dasatinib. No significant difference in the emotional
perception of TFR according to the type of TKI was
observed. Confidence in the physician and the possibility
of eliminating toxicities resulted in the most frequently reported
reasons for willingness to attempt TFR. In that series, only 7
participants expressed anxiety or fear about stopping treatment
(Villemagne Sanchez et al., 2018).
Moreover, the study by Graffigna et al. (2017), exploring
reactions to the possibility of interrupting treatment, is in some
way a pre-step of our study that interviewed only patients who
really entered into a clinical trial with the goal of TFR.
Our findings showed that the way in which patients gave
sense to the experience of TFR depended on their whole
journey, beginning from the diagnosis. TFR was also lived in
an ambivalent way: with hope, as a possibility to discontinue
therapy, but also with fears, because often patients linked
the treatment with their life safety. In this regard, many
patients who discontinue the TKI (estimated to be up to
30%) experience musco-skeletal pain (Hochhaus et al., 2017),
which is described as “TKI withdrawal syndrome” (Richter
et al., 2014; Galimberti et al., 2015). This possible event also
needs to be very carefully explained to the patients, as the
first thought when experiencing those symptoms might be that
they have a relapse.
Our interviews showed that patients were reluctant to
think that the success of TFR could lead to healing. Indeed,
we have to consider that for many years physicians told
patients that TKI was saving their lives, and that they
needed to take it every day because compliance is the first
step for achieving a good response (and survival). Now the
physicians need to deal with these new messages, as newest
clinical data clearly show that a life without drugs and
a potential “operative cure” is possible. Understanding the
patient’s perspective and lived experiences is undoubtedly an
asset for more efficient health interventions and improved
clinical compliance.
Finally, the way in which our sub-study CML patients
gave sense to the experience of the early trial discontinuation
in the light of their illness history is likewise a relevant
finding of our work: this result is really new, but some
studies seemed to point in the same direction, as they
proved that patients’ emotional experience of being involved
in a clinical trial depends on the feelings related to the
disease itself and experienced before entering into a trial.
Wineman et al. (1996), for example, suggested that subjects
entering into a clinical trial for multiple sclerosis with
high levels of illness uncertainty and stress were likely to
experience mood disturbances and felt less hopeful about
treatment effectiveness. Moreover, the pattern of relationships
among uncertainty, coping, hopefulness, and mood did not
change throughout participation in the experimental trial
(Wineman et al., 2003).
Limits
The methodology used, although fundamental for the aim,
implies some limits that the qualitative research could present.
In particular, the study is based on a small sample of CML
patients. However, we interviewed only patients receiving
nilotinib as part of the ENESTPath trial; this ensures a
population that comes from various hospitals in different
areas of Italy and that is homogenous in terms of treatment
duration and therapy management. As in all qualitative studies,
the findings are not statistically generalizable, but offer some
clinically useful insights to improve CML patients’ care. The
study constitutes an interesting stimulus to favor a process
of understanding CML from a patient-centered view, which
could help physicians to improve their relationship with patients
and the confidence that emerged as fundamental in order
to stimulate in patients the willingness to being engaged in
a clinical trial.
CONCLUSION
The Italian sub-study clearly showed how CML patients perceive
early trial discontinuation, and the way they give sense to it
appears to have a strict relationship with individual disease
experience. This qualitative analysis helps in understanding
patients’ perspective, both in terms of getting access to the
inner subjective experience of having CML and of being
involved in a trial or its cessation. The insights provided show
once again that patients’ experience of the diagnosis, in its
primordial ambivalent nature, with the co-existence of opposite
feelings, influenced patients’ perception of the disease, of the
treatment, as well as of the eventual patient’s failure of the
clinical trial. There is a need to develop strategies to cope
with patients’ emotional experience and guarantee that their
psycho-emotional wellbeing is one of the objectives of each
new clinical trial.
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